The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B

Samer E. Kaba, Franco DeMonte, Janet M. Bruner, Athanassios P. Kyritsis, Kurt Jaeckle, Victor Levin, W. K.Alfred Yung

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

OBJECTIVE: Recurrent malignant meningiomas and unresectable meningiomas represent a great therapeutic challenge after the failure of radiation therapy. No effective chemotherapy has been found. We report the preliminary results of the treatment of patients with recurrent unresectable or malignant meningiomas with recombinant interferon alpha-2B (IFN-α-2B). METHOD: Each of six patients with either a recurrent malignant meningioma or an unresectable meningioma was treated with IFN-α, administered subcutaneously at a dosage of 4 mU/m2 per day, 5 days per week. Two of the six meningiomas were regular, one was atypical, and three were malignant. RESULTS: Five of six patients exhibited positive response to treatment; with stabilization of the size of the tumor in four patients and slight regression in one. The responses observed lasted from 6 to 14 months. The toxicity associated with prolonged use of IFN-α was mild and well tolerated. CONCLUSION: These results suggest that IFN-α is effective in the treatment of recurrent malignant meningiomas.

Original languageEnglish (US)
Pages (from-to)271-275
Number of pages5
JournalNeurosurgery
Volume40
Issue number2
DOIs
StatePublished - Feb 1 1997

Fingerprint

interferon alfa-2b
Meningioma
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

Kaba, S. E., DeMonte, F., Bruner, J. M., Kyritsis, A. P., Jaeckle, K., Levin, V., & Yung, W. K. A. (1997). The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery, 40(2), 271-275. https://doi.org/10.1097/00006123-199702000-00007
Kaba, Samer E. ; DeMonte, Franco ; Bruner, Janet M. ; Kyritsis, Athanassios P. ; Jaeckle, Kurt ; Levin, Victor ; Yung, W. K.Alfred. / The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. In: Neurosurgery. 1997 ; Vol. 40, No. 2. pp. 271-275.
@article{f568d15d546541aa9eb453dbe902657e,
title = "The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B",
abstract = "OBJECTIVE: Recurrent malignant meningiomas and unresectable meningiomas represent a great therapeutic challenge after the failure of radiation therapy. No effective chemotherapy has been found. We report the preliminary results of the treatment of patients with recurrent unresectable or malignant meningiomas with recombinant interferon alpha-2B (IFN-α-2B). METHOD: Each of six patients with either a recurrent malignant meningioma or an unresectable meningioma was treated with IFN-α, administered subcutaneously at a dosage of 4 mU/m2 per day, 5 days per week. Two of the six meningiomas were regular, one was atypical, and three were malignant. RESULTS: Five of six patients exhibited positive response to treatment; with stabilization of the size of the tumor in four patients and slight regression in one. The responses observed lasted from 6 to 14 months. The toxicity associated with prolonged use of IFN-α was mild and well tolerated. CONCLUSION: These results suggest that IFN-α is effective in the treatment of recurrent malignant meningiomas.",
author = "Kaba, {Samer E.} and Franco DeMonte and Bruner, {Janet M.} and Kyritsis, {Athanassios P.} and Kurt Jaeckle and Victor Levin and Yung, {W. K.Alfred}",
year = "1997",
month = "2",
day = "1",
doi = "10.1097/00006123-199702000-00007",
language = "English (US)",
volume = "40",
pages = "271--275",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Kaba, SE, DeMonte, F, Bruner, JM, Kyritsis, AP, Jaeckle, K, Levin, V & Yung, WKA 1997, 'The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B', Neurosurgery, vol. 40, no. 2, pp. 271-275. https://doi.org/10.1097/00006123-199702000-00007

The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. / Kaba, Samer E.; DeMonte, Franco; Bruner, Janet M.; Kyritsis, Athanassios P.; Jaeckle, Kurt; Levin, Victor; Yung, W. K.Alfred.

In: Neurosurgery, Vol. 40, No. 2, 01.02.1997, p. 271-275.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B

AU - Kaba, Samer E.

AU - DeMonte, Franco

AU - Bruner, Janet M.

AU - Kyritsis, Athanassios P.

AU - Jaeckle, Kurt

AU - Levin, Victor

AU - Yung, W. K.Alfred

PY - 1997/2/1

Y1 - 1997/2/1

N2 - OBJECTIVE: Recurrent malignant meningiomas and unresectable meningiomas represent a great therapeutic challenge after the failure of radiation therapy. No effective chemotherapy has been found. We report the preliminary results of the treatment of patients with recurrent unresectable or malignant meningiomas with recombinant interferon alpha-2B (IFN-α-2B). METHOD: Each of six patients with either a recurrent malignant meningioma or an unresectable meningioma was treated with IFN-α, administered subcutaneously at a dosage of 4 mU/m2 per day, 5 days per week. Two of the six meningiomas were regular, one was atypical, and three were malignant. RESULTS: Five of six patients exhibited positive response to treatment; with stabilization of the size of the tumor in four patients and slight regression in one. The responses observed lasted from 6 to 14 months. The toxicity associated with prolonged use of IFN-α was mild and well tolerated. CONCLUSION: These results suggest that IFN-α is effective in the treatment of recurrent malignant meningiomas.

AB - OBJECTIVE: Recurrent malignant meningiomas and unresectable meningiomas represent a great therapeutic challenge after the failure of radiation therapy. No effective chemotherapy has been found. We report the preliminary results of the treatment of patients with recurrent unresectable or malignant meningiomas with recombinant interferon alpha-2B (IFN-α-2B). METHOD: Each of six patients with either a recurrent malignant meningioma or an unresectable meningioma was treated with IFN-α, administered subcutaneously at a dosage of 4 mU/m2 per day, 5 days per week. Two of the six meningiomas were regular, one was atypical, and three were malignant. RESULTS: Five of six patients exhibited positive response to treatment; with stabilization of the size of the tumor in four patients and slight regression in one. The responses observed lasted from 6 to 14 months. The toxicity associated with prolonged use of IFN-α was mild and well tolerated. CONCLUSION: These results suggest that IFN-α is effective in the treatment of recurrent malignant meningiomas.

UR - http://www.scopus.com/inward/record.url?scp=0031030863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031030863&partnerID=8YFLogxK

U2 - 10.1097/00006123-199702000-00007

DO - 10.1097/00006123-199702000-00007

M3 - Article

C2 - 9007858

AN - SCOPUS:0031030863

VL - 40

SP - 271

EP - 275

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 2

ER -

Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle K, Levin V et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997 Feb 1;40(2):271-275. https://doi.org/10.1097/00006123-199702000-00007